Abstract
Novel 2-[3-(4-bromo-2-fluorobenzyl)-4-oxo-3,4-dihydro-1-phthalazinyl]acetic acid hydrazones were synthesized from phthalic anhydride by a six step synthesis and evaluated for in vitro, in vivo activities against eight mycobacterial species and Mycobacterium tuberculosis (MTB) isocitrate lyase (ICL) enzyme inhibition studies. Among twenty six compounds N1-[(4-nitrophenyl)methylene]-2-[3-(4-bromo-2-fluorobenzyl)-4-oxo-1,2,3,4-tetrahydro-1-phthalazinyl]ethanohydrazide (7j) was found to be the most active compound in-vitro with MICs of 0.18 and < 0.09 μM against log-phase cultures of MTB and multi-drug resistant MTB respectively. Compound 7j inhibited all the eight mycobacterial species with MIC ranging from < 0.09-12.25 μM and was not toxic to Vero cell lines till 122.5 μM. Seven compounds were tested against starved culture of MTB and they inhibited with MICs ranging from 2.88-8.91 μM. Some compounds showed 45- 61% inhibition against MTB ICL enzyme at 10 μM. In the in vivo animal model 7j decreased the bacterial load in lung and spleen tissues with 1.87 and 3.03-log10 protections respectively at 25 mg/kg body weight dose.
Keywords: Phthalazine, Antimycobacterial, Mycobacterium tuberculosis, Isocitrate lyase
Medicinal Chemistry
Title: Novel Pthalazinyl Derivatives: Synthesis, Antimycobacterial Activities, and Inhibition of Mycobacterium Tuberculosis Isocitrate Lyase Enzyme
Volume: 5 Issue: 5
Author(s): D. Sriram, P. Yogeeswari, P. Senthilkumar, S. Dewakar, N. Rohit, B. Debjani, Pritesh Bhat, B. Veugopal, V. V.S. Pavan and H. M. Thimmappa
Affiliation:
Keywords: Phthalazine, Antimycobacterial, Mycobacterium tuberculosis, Isocitrate lyase
Abstract: Novel 2-[3-(4-bromo-2-fluorobenzyl)-4-oxo-3,4-dihydro-1-phthalazinyl]acetic acid hydrazones were synthesized from phthalic anhydride by a six step synthesis and evaluated for in vitro, in vivo activities against eight mycobacterial species and Mycobacterium tuberculosis (MTB) isocitrate lyase (ICL) enzyme inhibition studies. Among twenty six compounds N1-[(4-nitrophenyl)methylene]-2-[3-(4-bromo-2-fluorobenzyl)-4-oxo-1,2,3,4-tetrahydro-1-phthalazinyl]ethanohydrazide (7j) was found to be the most active compound in-vitro with MICs of 0.18 and < 0.09 μM against log-phase cultures of MTB and multi-drug resistant MTB respectively. Compound 7j inhibited all the eight mycobacterial species with MIC ranging from < 0.09-12.25 μM and was not toxic to Vero cell lines till 122.5 μM. Seven compounds were tested against starved culture of MTB and they inhibited with MICs ranging from 2.88-8.91 μM. Some compounds showed 45- 61% inhibition against MTB ICL enzyme at 10 μM. In the in vivo animal model 7j decreased the bacterial load in lung and spleen tissues with 1.87 and 3.03-log10 protections respectively at 25 mg/kg body weight dose.
Export Options
About this article
Cite this article as:
Sriram D., Yogeeswari P., Senthilkumar P., Dewakar S., Rohit N., Debjani B., Bhat Pritesh, Veugopal B., Pavan V.S. V. and Thimmappa M. H., Novel Pthalazinyl Derivatives: Synthesis, Antimycobacterial Activities, and Inhibition of Mycobacterium Tuberculosis Isocitrate Lyase Enzyme, Medicinal Chemistry 2009; 5 (5) . https://dx.doi.org/10.2174/157340609789117886
DOI https://dx.doi.org/10.2174/157340609789117886 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Detection of the Incidence of Infections and Acute Biochemical Changes in Diffused Large B-Cell Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) with and without Rituximab
Current Drug Safety On the Design of Broad Based Screening Assays to Identify Potential Pharmacological Chaperones of Protein Misfolding Diseases
Current Topics in Medicinal Chemistry Bibliometric Assessment of the Latin-American Contributions in Dengue
Recent Patents on Anti-Infective Drug Discovery On the Contribution of Molecular Topology to Drug Design and Discovery
Current Computer-Aided Drug Design Integrating Virtual Screening and Combinatorial Chemistry for Accelerated Drug Discovery
Combinatorial Chemistry & High Throughput Screening Goniothalamin-Related Styryl Lactones: Isolation, Synthesis, Biological Activity and Mode of Action
Current Medicinal Chemistry Hybolites: Novel Therapeutic Tools for Targeting Hyperstructures in Bacteria
Recent Patents on Anti-Infective Drug Discovery Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus
Current Rheumatology Reviews Reaction of Some Substituted 3-Aryl-4-formylsydnones with Tetra-Oacetyl- β-D-galactopyranosyl)thiosemicarbazide
Letters in Organic Chemistry History of Autoimmune Pancreatitis and Mikuliczs Disease
Current Immunology Reviews (Discontinued) Exploring Novel Immunological Interventions Using Immunoinfectomics
Anti-Infective Agents The Chemical Dynamics of NO and Reactive Nitrogen Oxides: A Practical Guide
Current Molecular Medicine The Diagnosis of Large Airway Pathology and the Role of Rigid Bronchoscopy
Current Respiratory Medicine Reviews Update on the Development of TB Vaccines
Current Pharmaceutical Biotechnology Medicinal and Beneficial Health Applications of Tinospora cordifolia (Guduchi): A Miraculous Herb Countering Various Diseases/Disorders and its Immunomodulatory Effects
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery New Pyrroles with Potential Antimycobacterial, Antifungal and Selective COX-2 Inhibiting Activities. Synthetic Methodologies
Current Organic Chemistry Insights Into the Molecular Aspects of Neuroprotective Bacoside A and Bacopaside I
Current Neuropharmacology Nonprofit Pharma: Solutions to What Ails the Industry
Current Medicinal Chemistry Protective Mechanisms of Helminths Against Reactive Oxygen Species are Highly Promising Drug Targets
Current Medicinal Chemistry The Introduction of Hydrazone, Hydrazide, or Azepane Moieties to the Triterpenoid Core Enhances an Activity Against <i>M. tuberculosis</i>
Medicinal Chemistry